207 related articles for article (PubMed ID: 31670985)
1. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
Feng Y; Cu X; Xin M
Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
[No Abstract] [Full Text] [Related]
2. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
Norman P
Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
[TBL] [Abstract][Full Text] [Related]
8. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
9. Selective PI3Kδ inhibitors, a review of the patent literature.
Norman P
Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
[TBL] [Abstract][Full Text] [Related]
10. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
12. Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors.
Sun J; Feng Y; Huang Y; Zhang SQ; Xin M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127457. PubMed ID: 32755681
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
14. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
15. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
17. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
[TBL] [Abstract][Full Text] [Related]
18. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
[Next] [New Search]